Arcturus Therapeutics Sets 2024 Milestones for mRNA Pipeline

Arcturus Therapeutics is entering a critical phase for its mRNA pipeline. The company aims to advance two lead therapeutic candidates while using its vaccine business to maintain operations through 2028. With over $200 million in liquidity, the company is prioritizing development milestones for its cystic fibrosis and ornithine transcarbamylase (OTC) deficiency programs.

"We are not modulating a broken or dysfunctional transporter. We are building a new one. Arcturus’ drug, ARCT-032, is a messenger RNA molecule that expresses or makes a brand-new CFTR protein in the lung," management stated during a recent investor summit.

Clinical Milestones for ARCT-032 and ARCT-810

The company is focusing on two primary clinical developments:

• ARCT-032 (Cystic Fibrosis): Arcturus expects to decide whether to advance this candidate into Phase III trials in Q4 2024. The program is supported by a $40 million commitment from Thermo Fisher.
• ARCT-810 (OTC Deficiency): Regulatory guidance and clinical data for this injectable mRNA therapy are expected before September 30, 2024.

Strategic Focus on Pediatric Markets

Arcturus is targeting pediatric populations for its therapeutic candidates. In discussing the market potential for its OTC deficiency program, the company highlighted the demographics that define its commercial strategy.

"The lion’s share of the commercial opportunity is in pediatrics. The lion’s share of the opportunity is in the X-linked boys. This is an X-linked genetic disorder that is potentially fatal for young males, and that’s where the unmet medical need is, that’s where the commercial opportunity is," the company noted.

Financial Runway and Operational Sustainability

According to recent conference disclosures, the firm’s liquidity position of over $200 million provides a financial runway extending through 2028. This capital base supports the transition from early-stage research to late-stage clinical trials, reducing the immediate need for external financing as the company evaluates its lead assets.

By utilizing revenue from its vaccine business, Arcturus funds the development of its mRNA platform, which relies on proprietary lipid nanoparticle delivery technology. The Q4 decision for ARCT-032 marks a transition for the company as it moves from evaluating efficacy in smaller cohorts to potentially pursuing large-scale registrational studies.